Incidence of Contrast-Induced Nephropathy in Patients With Multiple Myeloma Undergoing Contrast-Enhanced CT

被引:33
作者
Pahade, Jay K. [1 ]
LeBedis, Christina A. [1 ]
Raptopoulos, Vassilios D. [1 ]
Avigan, David E. [2 ]
Yam, Chun S. [1 ]
Kruskal, Jonathan B. [1 ]
Pedrosa, Ivan [1 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Radiol, Sch Med, Boston, MA 02215 USA
[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Hematol Oncol, Sch Med, Boston, MA 02215 USA
关键词
contrast-induced nephropathy; multiple myeloma; ACUTE-RENAL-FAILURE; INDUCED NEPHROTOXICITY; RISK; INSUFFICIENCY; PATHOGENESIS; IODIXANOL; COHORT;
D O I
10.2214/AJR.10.5152
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. The purpose of this article is to evaluate the incidence of contrast-induced nephropathy (CIN) and the effects of associated risk factors in patients with multiple myeloma undergoing contrast-enhanced CT (CECT) with IV administration of nonionic iodinated contrast agent. MATERIALS AND METHODS. This retrospective review of medical records identified patients with a diagnosis of myeloma who underwent a CECT examination of the chest, abdomen, or pelvis between January 1, 2005, and December 1, 2008. Analysis for CIN, as defined by an increase in creatinine level after the CECT examination of 25% or more, or of 0.5 mg/dL, compared with the level before the CECT examination, both within 48 hours and within 7 days, was performed. Statistical correlations between the development of CIN and creatinine level before CECT examination, patient location, type and amount of contrast agent, blood urea nitrogen-creatinine ratio, history of diabetes, hypercalcemia, Bence Jones proteinuria, beta(2)-microglobulin level, albumin level, International Myeloma Staging System stage, and history of myeloma provided at the time the CT examination was ordered were calculated. RESULTS. Forty-six patients who completed 80 unique examinations were included; their average creatinine level before CECT examination was 0.97 mg/dL. There was no significant difference in the average creatinine levels before CT examination between patients without and those with CIN. Four (5%) and 12 (15%) patients developed CIN within 48 hours and 7 days, respectively. Only serum beta(2)-microglobulin level showed a statistically significant (p = 0.03) correlation with the development of CIN. CONCLUSION. The incidence of CIN in patients with multiple myeloma with a normal creatinine level is low and correlates with beta(2) -microglobulin levels. The administration of contrast agent in this patient population is safe but should be based on the potential benefit of the examination and the expected low risk of developing CIN.
引用
收藏
页码:1094 / 1101
页数:8
相关论文
共 35 条
  • [1] Multiple myeloma: Clinical review and diagnostic imaging
    Angtuaco, EJC
    Fassas, ABT
    Walker, R
    Sethi, R
    Barlogie, B
    [J]. RADIOLOGY, 2004, 231 (01) : 11 - 23
  • [2] [Anonymous], MAN CONTR MED VERS 6
  • [3] Contrast-induced nephropathy: Contrast material not required?
    Baumgarten, Deborah A.
    Ellis, James H.
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2008, 191 (02) : 383 - 386
  • [4] Pathogenesis and progression of monoclonal gammopathy of undetermined significance
    Blade, J.
    Rosinol, L.
    Cibeira, M. T.
    de Larrea, C. F.
    [J]. LEUKEMIA, 2008, 22 (09) : 1651 - 1657
  • [5] Background Fluctuation of Kidney Function Versus Contrast-Induced Nephrotoxicity
    Bruce, Richard J.
    Djamali, Aji
    Shinki, Kazuhiko
    Michel, Steven J.
    Fine, Jason P.
    Pozniak, Myron A.
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2009, 192 (03) : 711 - 718
  • [6] Iodixanol: Risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations
    Cheruvu, Bharadwaj
    Henning, Kathleen
    Mulligan, Janine
    Klippenstein, Donald
    Lawrence, David
    Gurtoo, Lalit
    Gottlieb, Ronald H.
    [J]. JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2007, 31 (04) : 493 - 498
  • [7] ACUTE-RENAL-FAILURE IN PATIENTS WITH MULTIPLE-MYELOMA
    COHEN, DJ
    SHERMAN, WH
    OSSERMAN, EF
    APPEL, GB
    [J]. AMERICAN JOURNAL OF MEDICINE, 1984, 76 (02) : 247 - 256
  • [8] Pathogenesis and treatment of renal failure in multiple myeloma
    Dimopoulos, M. A.
    Kastritis, E.
    Rosinol, L.
    Blade, J.
    Ludwig, H.
    [J]. LEUKEMIA, 2008, 22 (08) : 1485 - 1493
  • [9] Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance
    Eleutherakis-Papaiakovou, V.
    Bamias, A.
    Gika, D.
    Simeonidis, A.
    Pouli, A.
    Anagnostopoulos, A.
    Michali, E.
    Economopoulos, T.
    Zervas, K.
    Dimopoulos, M. A.
    [J]. LEUKEMIA & LYMPHOMA, 2007, 48 (02) : 337 - 341
  • [10] IV contrast administration for CT: A survey of practices for the screening and prevention of contrast nephropathy
    Elicker, BM
    Cypel, YS
    Weinreb, JC
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2006, 186 (06) : 1651 - 1658